Skip to main content

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC

Trial Status: Active

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced Merkel cell carcinoma (MCC) or cutaneous squamous cell carcinoma (cSCC) will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and / or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design).

Inclusion Criteria

  • Life expectancy ≥ 3 months at recruitment
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at the time of study treatment initiation.
  • Males or females with histologically confirmed diagnosis of advanced Merkel cell carcinoma (MCC) or cutaneous squamous cell carcinoma (cSCC)
  • Patients must have progressed despite standard therapy(ies) or are intolerant to or refused standard therapy(ies).
  • Clinically measurable disease with at least 1 injectable lesion ≥ 3 mm in longest diameter; an injectable lesion is defined as an easily palpable superficial lesion (cutaneous, subcutaneous or lymph nodal metastasis) that can be accurately localized, stabilized by palpation, and is superficial enough to enable intralesional injection.
  • No known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe
  • The entry laboratory criteria for subject eligibility must be less than or equal to Grade 1 adverse event levels for the parameters tested as defined by CTCAE v5.0:
  • Bone Marrow Function:
  • Hemoglobin (Hb) > LLN 10 g/dL
  • White Blood Cell Count (WBC) > LLN 3,000 cells/mcL
  • Platelet count (PLT) > LLN - 75,000 /mcL
  • Blood Coagulation Parameters
  • PT, INR < 1.5 x institutional ULN unless patient is therapeutically anticoagulated. If on anticoagulation PT/INR need to be within appropriate anticoagulation limits for the clinical indication. Patients who are receiving anticoagulants may participate in the trial if their anticoagulation can be stopped safely for several days at the time of biopsy.
  • Renal Function
  • Serum Creatinine (SCr) < 1 - 1.5 x baseline; < 1 1.5 x ULN
  • Hepatic Function:
  • Blood bilirubin < 1 - 1.5 x ULN if baseline was normal; < 1 1.5 x baseline if baseline was abnormal
  • Serum Alanine Aminotransferase (ALT) < 1 - 3 x ULN if baseline was normal; 1.5 3 x baseline if baseline was abnormal
  • Serum Aspartate Aminotransferase (AST) < 1 - 3 x ULN if baseline was normal; 1.5 3 x baseline if baseline was abnormal
  • Alkaline Phosphatase (ALP) < 1 - 2.5 x ULN if baseline was normal; 2 2.5 x baseline if baseline was abnormal
  • Gamma Glutylamyltransferase (GGT) < 1 - 2.5 x ULN, if baseline was normal; 2 2.5 x baseline if baseline was abnormal
  • Males and females of reproductive potential must agree to continuously use adequate contraception prior to study entry and for up to 6 months thereafter. A female is of childbearing potential unless she has had a surgical procedure that would accomplish sterility such a bilateral tubal ligation, hysterectomy or has not had menses for the past 12 months.
  • Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment
  • Patient or legal representative must understand and sign a written informed consent form.

Exclusion Criteria

  • Concurrent use of any other investigational product or participation in another trial within 28 days before start of study treatment.
  • Have received oncologic therapy within 2 weeks of planned IFx-Hu2.0 injection
  • Presence or history of central nervous system metastasis [treated/stable brain metastasis are allowable when patients have received prior therapy for their brain metastases and their central nervous system (CNS) disease is radiographically stable (> 4 weeks)]
  • Pregnant or breastfeeding females and females desiring to become pregnant or breastfeed within the timeframe of this study
  • Concurrent steroid therapy (> 10 mg of daily prednisone equivalent) or other immunosuppressive therapies such as those needed for solid organ transplants and rheumatoid arthritis. Topical or inhaled steroids are allowable.
  • History of organ allograft transplantation
  • History of hemolytic anemia
  • History of significant tumor bleeding, or coagulation or bleeding disorders.
  • History of autoimmune disorder, with exception of patients with vitiligo or endocrine-related autoimmune conditions receiving appropriate hormonal supplementation who are eligible; systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks before recruitment
  • Major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
  • Leptomeningeal involvement regardless of treatment status
  • Active, clinically serious infections or other serious uncontrolled medical conditions such as HIV, HBV, HCV, and EBV infection
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements
  • Unwilling or unable to follow protocol requirements

California

Los Angeles
Los Angeles County-USC Medical Center
Status: ACTIVE
Contact: Charlean Ketchens
Phone: 323-865-3035
USC / Norris Comprehensive Cancer Center
Status: ACTIVE
Contact: Xiomara Menendez
Phone: 323-865-0212
Newport Beach
Hoag Memorial Hospital
Status: ACTIVE
Contact: Cristina de Leon
Phone: 949-764-5543

Florida

Tampa
Moffitt Cancer Center
Status: ACTIVE
Contact: Andrew S. Brohl
Phone: 813-745-4673

Massachusetts

Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE

Utah

Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE

Approximately twenty adult patients (≥ 18 years of age), of any sex, ethnicity, and race with

histologically confirmed MCC or cSCC with accessible lesions, will be eligible for study

enrollment and treatment with IFx-Hu2.0 (i.e. 20 total patients across both indications).

These types of non-melanoma cancers are very rare in the pediatric population (< 18 years of

age) with only scattered case reports. The potential for development of this product for

pediatric subjects with MCC or cSCC will be evaluated after the results of this study are

available.

Patients must have at least one injectable lesion, defined as an easily palpable superficial

lesion (cutaneous, subcutaneous or lymph nodal metastasis) that can be accurately localized,

stabilized by palpation, and is superficial enough to enable intralesional injection.

To be eligible for this study, patients must have progressed despite standard therapy(ies),

or are intolerant to or refused standard therapy(ies).

Enrollees will receive IFx-Hu2.0 as a monotherapy at up to three time points. Depending on

the number of accessible lesions, a patient could receive up to three doses across three

lesions (one dose per lesion). The maximum number of lesions to be injected at any time point

under this protocol is three lesions. Blood will be collected from these patients prior to

treatment administration at every drug administration visit. These samples will be used to

perform CBC and clinical chemistry tests. A urine sample will be obtained for urinalysis for

protein and blood at the same frequency. Blood samples will also be drawn at the same

intervals for immune response evaluation as well.

This is primarily a safety study that is designed to evaluate IFx-Hu2.0 monotherapy and

provide foundational evidence to potentially support further studies investigating IFx-Hu2.0

+ anti-PD-1 combination therapy for patients with advanced MCC or cSCC.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Morphogenesis, Inc.

  • Primary ID NMSC 2019-01
  • Secondary IDs NCI-2020-00301
  • Clinicaltrials.gov ID NCT04160065